Since its launch on 2 January, Sebaashray has redefined healthcare accessibility in Diamond Harbour, touching the lives of ...

Methods Up to January 2022, 706 patients with confirmed genetic diagnosis of SMA-5q, or their parents, completed a self-reported questionnaire on natural history, genetic characteristics, drug ...

For 6 years, a college cross-country skier experiened pain that kept her from school and skiing. Finally, she was diagnosed ...

The Princess of Wales, 43, is undertaking two engagements in south Wales today, including a moving visit to Tŷ Hafan children ...

Failed Back Surgery Syndrome Market ... underscoring the importance of personalized treatment options and highlighting the benefits of minimally invasive procedures in addressing chronic back pain.

While there is no cure for SMA, several promising neuroprotective treatments have become available in the last decade. These include gene replacement therapies and medications, both of which ...

CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company with a market capitalization of $3.96 billion and an impressive 362.73% stock price surge over the past six months ...

As an update, the company was able to submit its BLA submit its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy [SMA]. The timeline for a regulatory application ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...

CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a biopharmaceutical company with a market capitalization of $3.96 billion and an impressive 362.73% stock price surge over the past six months, ...